Novel biomarkers rapidly differentiate neurological disorders

Researchers in Switzerland have shown that biomarkers in cerebrospinal fluid (CSF) can help rapidly differentiate multiple sclerosis (MS) from other neurological disorders in the acute phase.

According to Dr David Leppert of the University of Basel, Switzerland, it is often difficult to differentiate among the acute phases of neuromyelitis optica spectrum disorders (NMOSD), anti-myelin oligodendrocyte glycoprotein (MOG) antibody associated disease (MOGAD), and relapsing/remitting MS (RRMS).

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.